Market Access Biosimilars 2021 in Germany


The "Market Access Biosimilars 2021" symposium will deal with the changes in the German biosimilar market, including newest directive on economic prescriptions, therapy recommendations to physicians and pharmacists' role.

Speakers include representatives of HTA body G-BA, lawmakers, payers and industry.

More information

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.